To evaluate the marker potential of CD14+CD169+ cells in the pathogenic progression of CRC, we examined the phenotype and clinical relevance of circulating CD14+CD169+ monocytes and TIMs in CRC patients. The gene discussed is SIGLEC1; the disease is colorectal carcinoma.